Few interventions in modern trauma resuscitation have been adopted as swiftly or as enthusiastically as tranexamic acid. Within a decade of CRASH-2's publication, TXA had become embedded in pre-hospital protocols, military field medicine, and the ATLS curriculum itself. The 11th edition of the ATLS Student Course Manual endorses its early administration as part of haemorrhage control strategy, and most major trauma centres in the UK and North America now carry it from the point of wounding. Yet the evidence base underpinning this consensus is more fractured than it first appears, and a string of more recent trials has forced clinicians to ask uncomfortable questions about who actually benefits, when, and whether the celebrated three-hour window is a biological reality or a statistical artefact.
The CRASH-2 Foundation - and Its Fault Lines
The landmark CRASH-2 trial, published in the Lancet by Shakur and colleagues in 2010, enrolled over 20,000 adult trauma patients across 40 countries and demonstrated a statistically significant reduction in all-cause mortality when TXA was administered within three hours of injury compared with placebo. More striking still was the finding that administration after three hours was associated with increased risk of death from bleeding - a dose-response relationship running in reverse that transformed the three-hour threshold from a pragmatic guideline into something approaching doctrine.
The biological rationale appeared coherent. Traumatic coagulopathy activates the fibrinolytic system early, and TXA, a competitive inhibitor of plasminogen activation, should in principle interrupt this process most effectively while fibrinolysis is at its peak. The harm signal beyond three hours was attributed to the normal physiological suppression of fibrinolysis that occurs as the acute phase resolves - administering an anti-fibrinolytic into a system already shutting down fibrinolysis might paradoxically promote thrombosis.
The problem is that CRASH-2, for all its scale, was conducted across heterogeneous settings with limited physiological monitoring of fibrinolytic state. Patients were not stratified by injury severity scoring, and many were enrolled in low- and middle-income settings with very different baseline care standards to those in which ATLS candidates will practice. The absolute risk reduction, while statistically significant, was modest - roughly 1.5 percentage points in all-cause mortality - and the trial did not capture detailed data on the coagulation profile of enrolled patients at the time of randomisation.
Fibrinolysis Shutdown: The Complication Nobody Predicted
Perhaps the most intellectually challenging development in TXA research has come not from another large RCT, but from translational work examining the spectrum of fibrinolytic activity in injured patients. Research from the Denver group, led by Hunter Moore and colleagues, and published across several papers between 2014 and 2021, demonstrated that trauma-induced coagulopathy does not produce a uniform state of hyperfibrinolysis. Using viscoelastic assays including thromboelastography, their work characterised three phenotypes: hyperfibrinolysis, physiologic fibrinolysis, and - critically - fibrinolysis shutdown, in which fibrinolytic activity is paradoxically suppressed from the outset despite severe injury.
Fibrinolysis shutdown is not rare. It appears to represent the majority of severely injured patients, and it is associated with a distinct outcome profile including increased rates of multi-organ failure and venous thromboembolic complications. The concern is direct: if a significant proportion of trauma patients arrive in a state of fibrinolysis shutdown, administering TXA - a drug whose mechanism depends on there being active fibrinolysis to inhibit - may offer no benefit and could compound the pro-thrombotic milieu already present. This hypothesis remains incompletely tested in prospective trials, but it fundamentally challenges any approach that treats TXA as a universal early intervention rather than one targeted to a specific coagulopathic phenotype.
The STAAMP Trial: Prehospital TXA Under Scrutiny
The first major prospective trial specifically designed to test prehospital TXA in civilian trauma was the STAAMP trial, published by Guyette and colleagues in JAMA Surgery in 2021. Conducted across five US trauma systems, it randomised 1,002 patients to prehospital TXA versus placebo and found no statistically significant improvement in 30-day mortality in the primary analysis. A pre-specified subgroup of patients in haemorrhagic shock showed a signal toward benefit, but this did not achieve significance and the trial was not powered for subgroup analysis.
STAAMP was widely interpreted as equivocal rather than definitive, partly because it was underpowered relative to CRASH-2 and partly because the treatment effect, while absent in the overall population, appeared directionally consistent with benefit in the most severely injured. This ambiguity left the prehospital TXA debate unresolved - until a considerably larger and more rigorous trial arrived.
PATCH-Trauma: The Most Provocative Challenge Yet
Published in the New England Journal of Medicine in 2023, the PATCH-Trauma trial by Gruen and colleagues was a multicentre, double-blind, randomised controlled trial conducted across Australia, New Zealand, and Germany, enrolling 1,310 patients with traumatic haemorrhage who received prehospital TXA or placebo prior to hospital admission. The primary outcome was six-month neurological function, with 28-day mortality as a key secondary outcome. The results were striking in their clarity: there was no significant difference in either outcome between the two groups. If anything, there was a numerical trend toward harm in the TXA arm, though this did not reach significance.
PATCH-Trauma is the best-designed prospective trial of prehospital TXA in civilian trauma conducted to date, and its null result cannot be easily dismissed. The investigators enrolled patients in well-resourced prehospital systems with short transport times to major trauma centres — arguably the population most likely to benefit from early TXA based on the CRASH-2 rationale. That no benefit emerged in this population directly challenges the assumption that earlier is always better when administering TXA in civilian contexts, and raises the possibility that the CRASH-2 mortality benefit was driven partly by baseline care deficits in its trial settings rather than by TXA's pharmacological action alone.
What Does ATLS Teach, and Where Does the Evidence Now Sit?
The ATLS 11th edition recommends TXA within three hours of injury for patients with significant haemorrhage, acknowledging the CRASH-2 data and the time-critical nature of fibrinolysis. This recommendation has not changed despite the PATCH-Trauma findings, and it is worth understanding why. The in-hospital administration of TXA - particularly in patients with confirmed or suspected major haemorrhage - retains reasonable evidence support. The MATTERs study, a retrospective analysis by Morrison and colleagues published in Archives of Surgery in 2012, found TXA associated with improved survival in a military trauma population even after controlling for injury severity. The CRASH-3 trial, published in the Lancet in 2019, demonstrated a reduction in head injury-related death with TXA in patients with traumatic brain injury when given within three hours, specifically in those with mild to moderate injury.
What has shifted is the confidence with which TXA can be recommended as a blanket prehospital intervention in all civilian trauma patients. The PATCH-Trauma trial specifically undermines this extrapolation. The field is moving toward a more nuanced position: TXA probably benefits a definable subset of trauma patients - those with physiological evidence of hyperfibrinolysis and ongoing haemorrhage - but the tools to identify that subset in real time remain incompletely developed and unavailable at the roadside.
Implications for the ATLS Candidate
For those preparing for the ATLS examination, the core teaching remains that TXA should be administered early, ideally within three hours of injury, as part of damage control resuscitation. This is the position of the current curriculum and is unlikely to change pending formal guideline revision. However, the intellectually engaged candidate should understand that this recommendation is now contested at its edges - particularly in prehospital civilian contexts - and that the emerging science of fibrinolysis phenotyping may eventually require a more targeted approach to TXA administration. The examination will test you on what the manual says; the clinical world will increasingly require you to know why that guidance exists and where its boundaries lie.
The story of tranexamic acid in trauma is, in many ways, a story about how large simple trials generate transformative practice change, and how the nuance always arrives later. CRASH-2 changed the world. PATCH-Trauma and the fibrinolysis shutdown literature are now asking whether the world was changed in quite the right direction.